Abstract： Objective： To analyze the mechanism of Tetrastigma Radix in the treatment of rheumatoid arthritis （RA） using network pharmacology and molecular docking technology. Methods：Literature on the main active ingredients of Tetrastigma Radix was retrieved from databases including China National Knowledge Infrastructure （CNKI） ， Wanfang Data Knowledge Service Platform （Wanfang） ， and PubMed， and the SwissTargetPrediction database was used to screen their potential targets. RA-related genes were obtained from the GeneCards database， and the intersection between targets of active ingredients and disease genes was identified to determine potential therapeutic targets of Tetrastigma Radix for RA. Data were imported into Cytoscape 3.7.1 to construct a “drug-ingredient-target” network. The STRING database was used to build a protein-protein interaction （PPI） network and screen core targets. The Metascape platform was employed for Gene Ontology （GO） and Kyoto Encyclopedia of Genes and Genomes （KEGG） enrichment analyses of the core targets. Molecular docking validation of the main active ingredients of Tetrastigma Radix and core targets was performed using AutoDock Tools 1.5.6. Results： A total of 30 active ingredients were screened out from Tetrastigma Radix， corresponding to 430 potential targets. The main active ingredients obtained are methyl linolenate， quecetin， kaempferol， rhamnocitrin and resveratrol. A total of 1 186 RA-related disease targets were identified，and 46 key nodes were obtained after screening based on topological attribute values， primarily including albumin （ALB）， AKT serine/threonine kinase 1 （AKT1）， sarcoma protooncogene （SRC）， prostaglandin G/H synthase 2 （PTGS2）， matrix metalloproteinase 9 （MMP9）， epidermal growth factor receptor （EGFR）， mitogen-activated protein kinase 1 （MAPK1）， and other genes. GO enrichment analysis mainly involved kinase binding， transcription factor binding， response to peptides， and inflammatory responses. KEGG enrichment analysis identified 209 pathways， primarily including pathways in cancer， endocrine resistance pathways， cancer proteoglycans pathways， and phosphatidylinositol 3-kinase （PI3K）-AKT signaling pathways. Molecular docking results indicated that rhamnocitrin exhibited the most stable binding with MMP9， kaempferol with PIK3R1，resveratrol with MMP9，methyl linolenate with MMP9，and quercetin with PIK3R1. Conclusion：Network pharmacology analysis revealed that Tetrastigma Radix in the treatment of RA by targeting core genes such as MMP9， PIK3R1，and AKT1 through key active ingredients like methyl linolenate，quercetin，and kaempferol，and regulating pathways in cancer， endocrine resistance pathways， cancer proteoglycans pathways， and PI3K-AKT signaling pathway.